OCUGEN INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
OCUGEN INC. - More news...
OCUGEN INC. - More news...
- Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
- Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
- Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
- Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
- Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
- Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
- Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
- Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
- Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
- Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
- Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
- Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
- Ocugen to Present at Retinal Vascular Disease Drug Development Summit
- Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
- Ocugen Appoints Quan A. Vu as Chief Business Officer
- Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
- Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
- Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
- Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis
- Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
- Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
- Ocugen Provides Business Update & Third Quarter 2022 Financial Results
- Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
- Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
- Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
- Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
- Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
- Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
- Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology
